Elecoglipron (AZD5004/ECC5004) Advances with Multiple Clinical Data Presentations at ADA 2026

Eccogene and AstraZeneca to Present New Clinical Data on Elecoglipron at ADA 2026 Scientific Sessions Clinical-stage biopharmaceutical company Eccogene has announced that new clinical findings for elecoglipron (AZD5004/ECC5004), its investigational oral GLP-1 receptor agonist, will be featured at the 2026…










